Ma, Wen Wee http://orcid.org/0000-0001-5899-4034
Li, Jenny J.
Azad, Nilofer S.
Lam, Elaine T.
Diamond, Jennifer R.
Dy, Grace K.
Opyrchal, Mateusz
Zhi, Jay
Kramer, Douglas
Chan, Wing-Kai
Cutler, David
Kwan, Rudolf
Adjei, Alex A.
Jimeno, Antonio
Funding for this research was provided by:
Athenex, Inc.
Article History
Received: 8 February 2022
Accepted: 23 May 2022
First Online: 22 June 2022
Declarations
:
: NSA is a paid consultant for Mirati and QED; she receives institutional funding from Agios, Inc., Array, Atlas, Bayer HealthCare, BMS, Celgene, Debio, Eli Lilly and Company, EMD Serono, Incyte Corporation, Intensity, Merck & Co., Inc. and Taiho Pharmaceuticals Co., Ltd.; she participates on advisory boards for Incyte, QED, and Glaxo Smith Kline. JRD receives institutional research funding from Adlai Norte, Takeda, Gilead, Merck, AstraZeneca, Astellas, Abbvie, BMS, OnKure, Deciphera, Bayer, Hutchison, and Genentech; she is a consultant for Gilead and OnKure; she owns stock options in OnKure Therapeutics. MO receives research funding from Eli Lilly and Pfizer; he is a consultant for AstraZeneca and Novartis. AJ receives institutional research funding from Pfizer, Merck, SQZ Biotech, Moderna, Iovance, Khar, DebioPharm, Cantargia, and Sanofi; he owns stock options in Champions Oncology and Suvica. JZ, DK, WKC, DC, and RW are employees of Athenex, Inc. DC owns stock in Athenex, Inc. and Merck & Co., Inc. No conflicts of interests were disclosed by the other authors.
: This study was approved by the institutional review boards at each institution and was performed in accordance with the principles of the Declaration of Helsinki.
: Written informed consent to participate in the study was obtained from all participants included in the study.
: Written informed consent for publication of clinical data was obtained from all participants included in the study.